{
  "abstract": "Purpose: To evaluate changes in amyloid burden on serial amyloid PET before and after donanemab treatment in a real-world clinical cohort.\n\nMethods: This retrospective study included 20 consecutive patients who underwent serial amyloid PET before and after donanemab treatment. Quantitative analysis was performed using Centiloid values and tracer-specific standardized uptake value ratios (SUVr). Visual assessment was also performed to determine amyloid-positive or amyloid-negative status before and after treatment.\n\nResults: Centiloid values significantly decreased from 52.3 ± 23.4 at baseline to − 5.6 ± 16.5 at follow-up, with a mean change of − 58.0 (p < 0.001). All patients showed a reduction in Centiloid values. In the flutemetamol group (n = 12), pons-referenced SUVr significantly decreased, while in the florbetapir group (n = 8), cerebellar-referenced SUVr also showed significant reductions (both p < 0.001). On visual assessment, 17 of 20 patients (85%) converted from amyloid-positive to amyloid-negative status after treatment.\n\nConclusion: Serial amyloid PET demonstrated a substantial reduction in amyloid burden following donanemab treatment in this real-world cohort. Quantitative amyloid PET, particularly using Centiloid scaling, may be a useful tool for monitoring treatment response in clinical practice.\n\nSupplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11604-026-02054-x.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Radiology, Tokushima University Hospital, Tokushima, Japan",
    "Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan",
    "Department of Psychiatry, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Yoichi Otomi",
      "orcid": "0000-0002-8960-3662"
    },
    {
      "affs": [
        0
      ],
      "name": "Takayoshi Shinya"
    },
    {
      "affs": [
        0
      ],
      "name": "Hideki Otsuka"
    },
    {
      "affs": [
        0
      ],
      "name": "Hiroto Kasai"
    },
    {
      "affs": [
        0
      ],
      "name": "Tomoki Matsushita"
    },
    {
      "affs": [
        0
      ],
      "name": "Yukiko Takaoka"
    },
    {
      "affs": [
        0
      ],
      "name": "Yuka Hiroshima"
    },
    {
      "affs": [
        1
      ],
      "name": "Tomoyasu Matsubara"
    },
    {
      "affs": [
        1
      ],
      "name": "Koji Fujita"
    },
    {
      "affs": [
        2
      ],
      "name": "Yukiko Tomioka"
    },
    {
      "affs": [
        2
      ],
      "name": "Masahito Nakataki"
    },
    {
      "affs": [
        2
      ],
      "name": "Shusuke Numata"
    },
    {
      "affs": [
        1
      ],
      "name": "Yuishin Izumi"
    },
    {
      "affs": [
        0
      ],
      "name": "Masafumi Harada"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dywc2bsfmy6nr.bib",
  "cited_by": 0,
  "doi": "10.1007/s11604-026-02054-x",
  "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13722638/",
  "id": "dywc2bsfmy6nr",
  "issns": [
    "1867-1071",
    "1867-108X"
  ],
  "landing_url": "https://doi.org/10.1007/s11604-026-02054-x",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2737|Alzheimer's disease research and treatments"
    ]
  ],
  "openalex": "W7171368179",
  "pdf_url": "https://link.springer.com/content/pdf/10.1007/s11604-026-02054-x.pdf",
  "pmcid": "PMC13722638",
  "pmid": "42507054",
  "published": "2026-07-27",
  "publisher": null,
  "ris": "https://research.draconitic.com/paper/dywc2bsfmy6nr.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T12:21:25Z",
      "native_id": "PMC13722638",
      "source": "pmc",
      "url": "https://doi.org/10.1007/s11604-026-02054-x"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2737|Alzheimer's disease research and treatments",
      "subfield": "physiology"
    }
  ],
  "title": "Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study",
  "title_text": "Serial amyloid PET demonstrates marked reduction in amyloid burden following donanemab treatment: a real-world cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-04T12:21:25Z",
  "url": "https://research.draconitic.com/paper/dywc2bsfmy6nr",
  "venue": "Japanese Journal of Radiology",
  "versions": []
}